Screener
4D Molecular Therapeutics FDMT Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Cash and cash equivalents | $72,488 | $60,241 |
| Marketable securities | 318,404 | 342,414 |
| Prepaid expenses and other current assets | 14,472 | 10,479 |
| Total current assets | 405,364 | 413,134 |
| Marketable securities, long-term | 66,739 | 111,379 |
| Property and equipment, net | 13,587 | 14,867 |
| Operating lease right-of-use assets, net | 17,357 | 18,143 |
| Other assets | 9,858 | 9,188 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's total current assets?
- 4D Molecular Therapeutics (FDMT) reported total current assets of $405.36M in Q1 2026.
- How has 4D Molecular Therapeutics's total current assets changed year-over-year?
- 4D Molecular Therapeutics's total current assets increased by 21.9% year-over-year, from $332.57M to $405.36M.
- What is the long-term trend for 4D Molecular Therapeutics's total current assets?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's total current assets has grown at a 7.9% compound annual growth rate (CAGR), from $282.66M to $413.13M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about 4D Molecular Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude